1,195
Participants
Start Date
May 31, 2008
Primary Completion Date
August 31, 2010
Study Completion Date
October 31, 2012
Placebo
Four tablets once daily until disease progression
Abiraterone acetate
Four 250-mg tablets once daily until disease progression
Prednisone/prednisolone
5 mg twice daily until disease progression
Birmingham
Tucson
Beverly Hills
Duarte
Los Angeles
Marina del Rey
Sacramento
San Diego
San Francisco
Aurora
Bristol
New Haven
Stamford
Boca Raton
Fort Lauderdale
Fort Myers
West Palm Beach
Atlanta
Honolulu
Chicago
Galesburg
Indianapolis
Westwood
Wichita
Marrero
New Orleans
Baltimore
Boston
Detroit
Robbinsdale
St Louis
Billings
Omaha
Las Vegas
Box 302
East Setauket
New Hyde Park
New York
Stony Brook
Durham
Raleigh
Canton
Cincinnati
Portland
Philadelphia
Pittsburgh
Myrtle Beach
Chattanooga
Nashville
Dallas
Houston
San Antonio
Virgiania Beach
Seattle
Adelaide
Camperdown
Footscray
Geelong
Heidelberg
Herston
Hobart
Hornsby
Kogarah
Kurralta Park
Liverpool
Milton
Parkville
Perth
Subiaco
Wodonga
Wollongong
Linz
Salzburg
Vienna
Antwerp
Bonheiden
Brussels
Ghent
Hasselt
Kortrijk
Leuven
Liège
Roeselare
Edmonton
Kelowna
Vancouver
Victoria
Halifax
Hamilton
Toronto
Montreal
Regina
Calgary Ab
London
Angers
Caen
Cannes
Dijon
Lyon
Paris
Saint-Herblain
Vandœuvre-lès-Nancy
Villejuif
Aachen
Berlin
Dresden
Hamburg
Homburg/Saar
Pécs
Szombathely
Cork
Dublin
Nijmegen
Badalona
Barcelona
Madrid
Belfast
Birmingham
Cambridge
Glasgow
London
Manchester
Newcastle upon Tyne
Northwood
Oxford
Sutton
Whitchurch
Lead Sponsor
Cougar Biotechnology, Inc.
INDUSTRY